What Is TLC590?
TLC590 is an investigational drug currently being studied for postsurgical pain management. It is an extended-release injectable suspension of ropivacaine, a type of local anesthetic. Local anesthetics work by temporarily blocking nerve signals in a specific area of the body, which prevents pain sensations from reaching the brain.
The drug is formulated using lipid-based excipients to create a sustained-release liposome injectable suspension. This specialized formulation allows for the gradual and prolonged release of ropivacaine at the site of injection. This extended release is intended to provide long-lasting pain relief after surgical procedures, potentially reducing the need for frequent administration of other pain medications and improving patient comfort during the recovery phase.
Clinical trials are currently evaluating the safety and effectiveness of TLC590 across various surgical settings.
Uses and Conditions Under Study
TLC590 is being investigated primarily for the management of pain following surgical procedures. This includes general postsurgical pain and specific types of postoperative pain.
Postsurgical pain is a common experience after any operation, and effective management is crucial for patient recovery and well-being. Local anesthetics like ropivacaine, delivered in an extended-release formulation such as TLC590, are designed to provide targeted and prolonged pain relief directly at the surgical site. This approach aims to reduce the overall pain intensity and potentially decrease the reliance on systemic pain medications, which can have broader side effects.
Specific surgical conditions being studied include:
- Postsurgical Pain Management: Two trials are specifically focused on general postsurgical pain management.
- Postoperative Pain: One trial also addresses general postoperative pain.
- Hallux Valgus: One trial is investigating the use of TLC590 for pain management after surgery for hallux valgus, commonly known as a bunion. This condition involves a deformity of the big toe joint.
- Inguinal Hernia: Another trial is studying its use for pain after inguinal hernia repair, a common surgical procedure to fix a hernia in the groin area.
In total, five clinical trials have been conducted or are ongoing for TLC590, enrolling a total of 1,050 participants. Two of these trials are currently recruiting participants, while two have been completed. The first trial began on July 19, 2018, and the latest is expected to conclude by October 30, 2025.
Dosing
TLC590 is studied as an injectable suspension, designed for administration directly at the surgical site. It is typically prepared by reconstituting a lyophilized cake with a specific solution to form the ropivacaine liposome injectable suspension. This formulation allows for localized and extended pain relief.
In clinical trials, various strengths of TLC590 have been investigated to determine the most effective and safe dose for postsurgical pain management. Investigational doses have ranged from 152 mg to 588 mg. Specific doses studied include:
- 152 mg
- 190 mg
- 228 mg
- 380 mg
- 475 mg
- 490 mg
- 570 mg
- 588 mg
Participants in some trials were sequentially enrolled into increasing dose cohorts, starting from lower doses and progressing to higher doses of TLC590. This approach helps researchers evaluate the dose-response relationship and identify optimal dosing strategies. The specific dose used depends on the surgical procedure and the individual patient's needs, as determined by the study protocol.
Comparators in these studies have included Liposomal Bupivacaine, Bupivacaine 75mg, Ropivacaine, and Naropin 150mg.
Side Effects
In a Phase I/II dose-escalation study (NCT03591146) evaluating the safety and tolerability of TLC590 for postsurgical pain management, serious adverse events (SAEs) and treatment-related severe adverse events were monitored across different dose groups. Serious adverse events are any unfavorable and unintended signs, symptoms, or diseases that occur during a clinical trial and are considered life-threatening, require hospitalization, result in persistent or significant disability, or are otherwise medically important. This early-phase study did not report specific side effect frequencies or comparisons to a placebo group for individual adverse events. The number of such events observed were:
- For patients receiving Naropin (a comparator), 2 events were reported.
- For patients receiving TLC590 190mg, 2 events were reported.
- For patients receiving TLC590 380mg, 1 event was reported.
- For patients receiving TLC590 475mg, 2 events were reported.
- For patients receiving TLC590 570mg, 2 events were reported.
These numbers represent the total count of serious or severe treatment-related adverse events across the respective treatment arms during the study, indicating the overall safety profile observed in this initial investigation.
Clinical Trial Results
TLC590 for Postsurgical Pain Management
A Phase I/II dose-escalation study (NCT03591146) was conducted to evaluate the safety, pharmacokinetics (how the drug moves through the body), and exploratory efficacy of TLC590 for managing pain after surgery. Early-phase trials like this primarily focus on determining a safe dose range and understanding how the drug behaves in the body, while also looking for initial signs of effectiveness.
In this study, a key outcome measured was the occurrence of serious adverse events (SAEs) and severe adverse events related to the treatment. The study monitored these events across different doses of TLC590 and compared them to Naropin, another pain management medication. The number of serious or severe treatment-related adverse events reported were:
- For patients receiving Naropin, 2 events were observed.
- For patients receiving TLC590 190mg, 2 events were observed.
- For patients receiving TLC590 380mg, 1 event was observed.
- For patients receiving TLC590 475mg, 2 events were observed.
- For patients receiving TLC590 570mg, 2 events were observed.
While the trial aimed to evaluate efficacy, specific data on pain reduction or other direct measures of efficacy were not provided in the available results. The primary focus of the provided data was on the safety and tolerability profile of TLC590 across the tested dose ranges, which is crucial for advancing to larger efficacy trials.
Currently Recruiting Trials
TLC590 is currently being investigated in clinical trials for its potential in managing postsurgical pain. These studies aim to gather more information on how well TLC590 works and its safety profile for patients recovering from surgery.
One such opportunity is a NCT07222748, a pivotal Phase 3 study titled "A Study of TLC590 for Postsurgical Pain Following Bunionectomy." This trial is designed to evaluate the pain-relieving effectiveness and safety of TLC590 when administered via local infiltration in adult patients after bunionectomy surgery. It is a randomized, double-blind study that compares TLC590 against both a comparator drug (liposomal bupivacaine) and a placebo. The study aims to enroll approximately 300 participants, with TLC Biopharmaceuticals, Inc. serving as the sponsor.
Another ongoing study, NCT06574269, is a Phase 2 open-label trial focused on "A Study on TLC590 for Managing Postsurgical Pain." This research delves into the pharmacokinetics (how the body processes the drug), pharmacodynamics (how the drug affects the body), and overall safety of TLC590 across various surgical procedures. Researchers are working to identify the maximum tolerated dose (MTD) of TLC590 through careful monitoring by a Safety Monitoring Committee. This study, also sponsored by TLC Biopharmaceuticals, Inc., is targeting an enrollment of 120 participants across multiple cohorts to explore different dosages.
Where to Participate
Opportunities to participate in clinical trials for TLC590 are available across multiple sites in the United States. Currently, the studies are recruiting participants at 4 locations spanning 2 states.
Top participating cities include:
- Bellaire, Texas
- Houston, Texas
- Miami, Florida
- San Antonio, Texas
Eligibility criteria for these trials generally require participants to be between 18 and 70 years of age. All genders are welcome to participate. It is important to note that these studies are not seeking healthy volunteers; rather, they are specifically designed for individuals undergoing certain surgical procedures. Children are not eligible to participate in these particular trials.
Development Timeline
The journey of TLC590 began with its first clinical trial on 2018-07-19, marking the initial steps in its development. Since then, the program has expanded significantly, with the latest trial projected to conclude by 2025-10-30. Over this period, a total of 5 trials have been conducted or are ongoing, involving approximately 1,050 participants.
Early development efforts were driven by Taiwan Liposome Company, which sponsored 3 of these trials, with TLC Biopharmaceuticals, Inc. taking the lead on the remaining 2. The initial focus of TLC590's investigation was on conditions such as IBS-C and hyperphosphatemia. However, the pipeline has since broadened, expanding its scope to include Inguinal Hernia and, more recently, a significant focus on Postoperative Pain management.
TLC590 has progressed through various clinical phases, including two Phase 2 studies, one Phase 1/Phase 2 study, one Phase 2/Phase 3 study, and one pivotal Phase 3 trial. This progression reflects the ongoing commitment to thoroughly evaluate TLC590's potential as it moves closer to potentially becoming a new treatment option for patients.